Autologous circulating extracellular vesicles

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Key Research and Development Program of China and 2 more

Human trial1

Outcomes

Senescent chondrocytes

downin humans1

1 study

Autologous circulating extracellular vesicles decrease senescent chondrocytes in humans.
“autologous circulating extracellular vesicles (C-EVs) possessed significant therapeutic potential for TMJ-OA through the targeted removal of senescent chondrocytes”
Human trial
Circulating Metabolites Treat Human TMJ-OA by Eliminating Senescent Chondrocytes via the C1QBP/C1q/p14ARF Axis
Journal of extracellular vesicles31 Jan 2026

Latest

1 in 12 months

Journal of Extracellular Vesicles31 Jan

Circulating Metabolites Treat Human TMJ-OA by Eliminating Senescent Chondrocytes via the C1QBP/C1q/p14ARF Axis

Randomised trial in peopleInterventions

Paper

Autologous circulating extracellular vesicles

Outcomes

Latest

Circulating Metabolites Treat Human TMJ-OA by Eliminating Senescent Chondrocytes via the C1QBP/C1q/p14ARF Axis

Related